A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients with Opioid Dependence Transitioned from a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine®

Grants and Contracts Details

StatusFinished
Effective start/end date7/29/14 → 6/30/15

Funding

  • Braeburn Pharmaceuticals: $109,249.00